Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
1.
Arthritis Rheum ; 61(3): 336-43, 2009 Mar 15.
Artigo em Inglês | MEDLINE | ID: mdl-19248124

RESUMO

OBJECTIVE: To analyze a population-based cohort of women in order to establish normal values of joint space width (JSW) and to evaluate the existence of age-related joint space loss (JSL). METHODS: Knee radiographs were performed 4 years apart in women from the OFELY (Os des Femmes de Lyon) Cohort. Posteroanterior radiographs of both knees were taken in semiflexion with a standardized fluoroscopically assisted protocol. Radiographs were qualitatively evaluated using a scoring system based on the Altman score that assessed joint space narrowing, osteophytes, and sclerosis for each tibiofemoral compartment and each side. For quantitative assessment, radiographs were digitized using a video camera, and specific software was used to measure JSW in every compartment. RESULTS: We evaluated the radiographs of 606 women (ages 39-90 years, mean 62 years) and found that in all subjects, JSW significantly decreased with age in every compartment (r = -0.12 to -0.16, P < 0.001), including in 358 subjects without any radiographic abnormality related to osteoarthritis (OA) at baseline. The longitudinal analysis confirmed a significant loss over 4 years of approximately 0.30 mm (6%) for the medial compartment. Multiple regression analysis did not identify significant predictors of JSL among clinical risk factors and biochemical markers of bone and cartilage turnover. CONCLUSION: In this first longitudinal study of a population-based cohort of women, we have established normal values of JSW and shown that JSW decreases with aging, especially at the medial compartment, even in subjects without any radiographic abnormalities related to OA.


Assuntos
Envelhecimento/fisiologia , Articulação do Joelho/diagnóstico por imagem , Articulação do Joelho/fisiologia , Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , Interpretação de Imagem Assistida por Computador , Articulação do Joelho/anatomia & histologia , Estudos Longitudinais , Pessoa de Meia-Idade , Osteoartrite do Joelho/diagnóstico por imagem , Radiografia , Valores de Referência
2.
Maturitas ; 44(4): 299-305, 2003 Apr 25.
Artigo em Inglês | MEDLINE | ID: mdl-12697371

RESUMO

OBJECTIVE: To assess the cost implications for a preventive treatment strategy for institutionalised elderly women with a combined 1200 mg/day calcium and 800 IU/day vitamin D(3) supplementation in seven European countries. DESIGN: Retrospective cost effectiveness analysis based on a prospective placebo-controlled randomised clinical trial. DATA SOURCES: Recently published cost studies in seven European countries. Clinical results from Decalyos, a 3-year placebo-controlled study in elderly institutionalised women. TRIALS: Decalyos study, with 36 months follow-up of 3270 mobile elderly women living in 180 nursing homes, allocated to two groups. One group received 1200 mg/day elemental calcium in the form of tricalcium phosphate together with 800 IU/day (20 microg) of cholecalciferol (vitamin D(3)), the other placebo. RESULTS: In the 36 months analysis of the Decalyos study, 138 hip fractures occurred in the group of 1176 women, receiving supplementation and 184 hip fractures in the placebo group of 1127 women. The mean duration of treatment was 625.4 days. Adjusted to 1000 women, 46 hip fractures were avoided by the calcium and vitamin D(3) supplementation. For all countries, the total costs in the placebo group were higher than in the group receiving supplementation, resulting in a net benefit of 79000-711000 per 1000 women. CONCLUSION: This analysis suggests that the supplementation strategy is cost saving. The results may underestimate the net benefits, as this treatment has also shown to be effective in decreasing the incidence of other non-vertebral fractures in elderly institutionalised women.


Assuntos
Fosfatos de Cálcio/administração & dosagem , Colecalciferol/administração & dosagem , Fraturas do Quadril/prevenção & controle , Osteoporose Pós-Menopausa/complicações , Idoso , Fosfatos de Cálcio/economia , Colecalciferol/economia , Análise Custo-Benefício , Custos de Medicamentos , Quimioterapia Combinada , Europa (Continente) , Feminino , Custos de Cuidados de Saúde , Fraturas do Quadril/economia , Fraturas do Quadril/etiologia , Humanos , Osteoporose Pós-Menopausa/economia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA